Anzeige
Erschienen in:
01.12.2013 | editorial
Antibody–drug conjugates (ADCs)—new targeted therapies
Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013
Einloggen, um Zugang zu erhaltenAbstract
The promise of all targeted therapies is the specific induction of cytotoxicity in malignant cells without adversely affecting normal tissues. Antibody–drug conjugates (ADCs) consist of a monoclonal antibody chemically linked to an anticancer agent, and are a niche class of drugs that raise great expectations, particularly as oncology drugs. Brentuximab vedotin and trastuzumab emtansine, both recently US Food and Drug Administration approved, open a promising new area in the therapy of hematologic malignancies and solid tumors. Further improvement of bioengineering and development of preclinical and clinical data are the challenges for the next generation of ADCs.
